Attovia Therapeutics Company Profile

Background

Attovia Therapeutics, established in June 2023, is a clinical-stage biotechnology company dedicated to developing innovative biotherapeutics for immune-mediated diseases. The company leverages its proprietary ATTOBODY™ platform to create biparatopic biologics that offer enhanced efficacy and a broader range of druggable targets compared to traditional approaches. Attovia's mission is to transform the treatment landscape for patients with immune-mediated conditions by delivering first-in-class and best-in-class therapies.

Key Strategic Focus

Attovia's strategic focus centers on:

• Advancing Lead Programs: Progressing ATTO-1310 and ATTO-3712 through clinical development to address chronic pruritus and atopic dermatitis, respectively.

• Expanding the Pipeline: Developing a diverse portfolio of multi-specific therapeutic candidates targeting various immune-mediated disorders, including inflammatory bowel disease.

• Enhancing the ATTOBODY™ Platform: Continuously refining the ATTOBODY™ technology to improve drug discovery and development capabilities.

Financials and Funding

Attovia has successfully secured substantial funding to support its initiatives:

• Series A Financing: In June 2023, the company launched with a $60 million Series A financing.

• Series B Financing: In May 2024, Attovia closed a $105 million oversubscribed Series B financing led by Goldman Sachs Alternatives, bringing the total capital raised to $165 million.

• Series C Financing: In April 2025, the company announced a $90 million Series C financing led by Deep Track Capital, with participation from new investors including Vida Ventures, Sanofi Ventures, and Mirae Asset Capital Life Science, as well as existing investors.

The funds are allocated to advance lead programs through clinical proof-of-concept, expand the pipeline, and further develop the ATTOBODY™ platform.

Pipeline Development

Attovia's pipeline includes:

• ATTO-1310: A first-in-class, half-life extended anti-IL-31 biologic currently in Phase 1 studies for chronic pruritus of unknown origin (CPUO). The Phase 1 study (NCT06787586) is a randomized, double-blind, placebo-controlled trial assessing safety, tolerability, and pharmacokinetics in healthy adults and patients with pruritic disease.

• ATTO-3712: A first-in-class anti-IL13 x IL31, half-life extended bispecific designed for atopic dermatitis and other inflammatory conditions. IND-enabling studies are underway, with Phase 1 clinical trials expected to commence in the second half of 2025.

• ATTO-004: A multi-specific drug candidate targeting inflammatory bowel disease, currently in preclinical development.

• Discovery Programs: Two additional multi-specific discovery-stage programs with potential applications across various immune-mediated diseases.

Technological Platform and Innovation

Attovia's proprietary ATTOBODY™ platform is distinguished by:

• Biparatopic Binding: Utilizing spatial positioning technology to achieve biparatopic target engagement, resulting in picomolar affinity and prolonged binding, which enhances biological activity.

• Modularity: Facilitating the engineering of multi-specific biologics with tunable half-lives, allowing for dosing intervals ranging from hours to weeks.

• High-Throughput Discovery: Employing an evolution-based discovery process that accelerates development and provides a diverse array of lead candidates, thereby expanding target biology coverage and mitigating development risks.

Leadership Team

Attovia's leadership comprises seasoned professionals with extensive experience in biotechnology and pharmaceutical industries:

• Tao Fu, MBA, M.S.: Founder and Chief Executive Officer, with over 25 years in business development, operations, and strategy, previously holding leadership roles at Zai Lab and Portola Pharmaceuticals.

• Steven Chan: Chief Financial Officer, bringing over 30 years of global financial strategy and operational experience, formerly CFO at Connect Biopharma.

• Hubert Chen, M.D., M.P.H.: Chief Medical Officer, an accomplished physician-scientist with 25 years of clinical and industry experience, previously Senior Vice President of Clinical Development at Krystal Biotech.

• Zaneta Odrowaz, Ph.D.: Chief Business Officer and Co-Founder, leading business development and operations, with prior experience at Frazier Life Sciences and Amunix Pharmaceuticals.

• Petter Veiby, Ph.D.: Chief Scientific Officer and Co-Founder, responsible for R&D strategy, with over 25 years in drug discovery and early development, formerly at Zai Lab and Takeda.

• Hangjun Zhan, Ph.D.: Chief Technology Officer and Co-Founder, with nearly 30 years of drug discovery experience, previously CSO at Alamar Biosciences.

Leadership Changes

Recent significant appointments include:

• Hubert Chen, M.D., M.P.H.: Appointed as Chief Medical Officer in March 2024, bringing extensive clinical development expertise.

• Steven Chan: Joined as Chief Financial Officer in October 2024, enhancing the company's financial strategy and operations.

• Board of Directors: In July 2024, Mitchell H. Gold, M.D., and Angie You, Ph.D., were elected as independent members, contributing decades of industry leadership experience.

Competitor Profile

Market Insights and Dynamics

The market for treatments targeting immune-mediated diseases is substantial and growing, driven by increasing prevalence and unmet medical needs. Key areas include chronic pruritus, atopic dermatitis, and inflammatory bowel disease, with a demand for therapies offering improved efficacy, safety, and patient convenience.

Competitor Analysis

• Sanofi and Regeneron Pharmaceuticals: Co-market Dupixent® (dupilumab), an IL-4 and IL-13 inhibitor approved for atopic dermatitis and other indications.

• Galderma: Developed Nemluvio (nemolizumab-ilto), an IL-31 inhibitor biologic approved for atopic dermatitis.

• Dermavant: Offers Vtama (tapinarof) cream, a nonsteroidal topical treatment for atopic dermatitis.

Attovia's ATTOBODY™ platform and pipeline candidates aim to provide differentiated solutions with potentially superior efficacy and dosing convenience.

Strategic Collaborations and Partnerships

Attovia has established strategic collaborations to bolster its capabilities:

• Alamar Biosciences: Licensed the ATTOBODY™ platform from Alamar Biosciences, enabling the development of novel biparatopic biologics.

• Investor Partnerships: Secured funding from prominent investors such as Goldman Sachs Alternatives, Deep Track Capital, and Sanofi Ventures, providing financial support and strategic guidance.

Operational Insights

Attovia's strategic considerations include:

• Differentiated Technology: Leveraging the ATTOBODY™ platform to develop biotherapeutics with enhanced potency and modularity.

• Focused Indications: Targeting immune-mediated diseases with high unmet needs, positioning the company to address significant market gaps.

• Experienced Leadership: A leadership team with extensive industry experience, driving efficient development and commercialization strategies.

Strategic Opportunities and Future Directions

Attovia's strategic roadmap encompasses:

• Clinical Advancement: Progressing ATTO-1310 and ATTO-3712 through clinical trials to achieve proof-of-concept and regulatory approvals.

• Pipeline Expansion: Developing additional multi-specific therapeutics targeting a range of immune-mediated diseases.

• Platform Enhancement: Continuing to refine the ATTOBODY™ platform to improve drug discovery efficiency and expand therapeutic applications.

• Strategic Partnerships: Exploring collaborations to enhance development capabilities and market reach.